← Leaderboards
Eric Siemers
Acumen Pharmaceuticals, Inc.
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–20$2M$1.5M$1M$500K$0
'18
'19
'20
Funding mix
By agency
NIH$3,451,620 · 1
By mechanism
U01$3,451,620 · 1
Top collaborators
No co-investigators on record.
Most similar at Acumen Pharmaceuticals, Inc.
Same institution · by research overlap
- Jeffrey L Ives$2,836,536
- William Goure$0
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposUnited States Food And Drug AdministrationContractsPharmacologic SubstanceRattusToxicologyImmunotherapyDoseMacaca FascicularisPharmaceutical PreparationsPreventAntibodiesS DiseaseS Disease RiskPlasmaClinical TrialsAcuteDisease ProgressionAmyloid Beta-ProteinInvestigational DrugsAnalytical MethodMonomerAbeta OligomerBehavioral
Grant awards (4)
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$797,087
U01 · FY2020 · AG · contact PI
Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development$262,500
U01 · FY2020 · AG · contact PI
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$1,135,517
U01 · FY2019 · AG · contact PI
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$1,256,516
U01 · FY2018 · AG · contact PI